Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Tony Pang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1327-9189; OpenAlex author ID A5023293738, A5114771042. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 10

  1. Absolute risk of pancreatic cancer in people with acute pancreatitis - theAustralian experience. Co-author DOI 10.1016/j.hpb.2026.05.011↗
  2. Impact of postoperative pancreatic fistula (POPF) on long-term outcomes of patients who underwent pancreatic cancer resection: systematic review and meta-analy… Co-author DOI 10.1016/j.suronc.2026.102459↗
  3. Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis. Co-author DOI 10.1053/j.gastro.2025.07.021↗
  4. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Co-author DOI 10.3389/fimmu.2022.1060957↗
  5. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Co-author DOI 10.1016/j.pan.2020.11.022↗
  6. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. Co-author DOI 10.3390/cancers13112763↗
  7. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. First author DOI 10.1038/s41416-020-0782-1↗
  8. An Orthotopic Resectional Mouse Model of Pancreatic Cancer. Co-author DOI 10.3791/61726↗
  9. Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. Co-author DOI 10.1093/carcin/bgx030↗
  10. Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility. Co-author DOI 10.1097/pat.0000000000000072↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoti Vivek Apte · 8 shared papers, 2017–2026 · strength 1.22
  2. Jeremy S. Wilson · 7 shared papers, 2017–2026 · strength 0.96
  3. David Goldstein · 6 shared papers, 2017–2022 · strength 0.69
  4. Zhihong Xu · 5 shared papers, 2017–2022 · strength 0.55
  5. Chamini Jayamali Perera · 3 shared papers, 2020–2026 · strength 0.50
  6. Srinivasa P. Pothula · 4 shared papers, 2017–2021 · strength 0.42
  7. S. M. Zahid Hosen · 2 shared papers, 2022–2026 · strength 0.39
  8. Marie Ranson · 2 shared papers, 2022–2026 · strength 0.39
  9. Lee S. Kyang · 1 shared paper, 2026 · strength 0.26
  10. Vincent W. T. Lam · 1 shared paper, 2026 · strength 0.26
  11. Rachel Ε. Neale · 1 shared paper, 2026 · strength 0.26
  12. Ashna A. Kumar · 1 shared paper, 2026 · strength 0.26
  13. Richard C. Turner · 1 shared paper, 2026 · strength 0.26
  14. Savio George Barreto · 1 shared paper, 2026 · strength 0.26
  15. Henry C. C. Pleass · 1 shared paper, 2026 · strength 0.26
  16. Adnan M. Nagrial · 1 shared paper, 2026 · strength 0.26
  17. Christopher Bahdah Nahm · 1 shared paper, 2026 · strength 0.26
  18. Mark E. Brooke‐Smith · 1 shared paper, 2026 · strength 0.26
  19. Mark Wong · 1 shared paper, 2026 · strength 0.26
  20. Lucas Wigston · 1 shared paper, 2026 · strength 0.26
  21. Daniel Gerald Croagh · 1 shared paper, 2026 · strength 0.26
  22. Mohammad Ali Moni · 1 shared paper, 2022 · strength 0.13
  23. Steve Gallinger · 1 shared paper, 2022 · strength 0.13
  24. Faiyaz Notta · 1 shared paper, 2022 · strength 0.13
  25. Takashi Murakami · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.